Audit: QRS - Ketoglutaric Acid for Hair Regrowth

Audit conducted on 11/10/2026 12:33 using AI4L / Opus 5.5

Iterations

Summary

Items Count
Total 94
Passed 87
Failed 0
N/A 7
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Lede, protocol, time cells, tiers, gates, markers and cadence all trace to ER sections (Conclusion, Therapeutic Protocol, Practical Considerations, Monitoring, Key Interactions)
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 “(theoretical)”, “(no safety data)”, “no hair-specific human protocol exists”, “animal data only” carried over
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Interaction severities (monitor/caution) and contraindication conditions match ER
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢  
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 Only brand Stemoxydine, present in ER for the same fact; no PMIDs or NCT IDs
1.6 The QRS does not introduce new attributions. 🟢  

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢  
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms expanded (AKG, eGFR, NSAIDs, OAT1); ‘telogen/anagen’ rendered as resting follicles entering growth
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 It DOES NOT address the reader directly 🟢  
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢  
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “longevity supplement”, “Longevity-style oral protocol”; no ‘anti-aging’
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 “oral” used throughout; no lay route phrasing

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢  
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All template spans present; marker_# expanded to 1-4, qualitative_item_# to 1-5
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 website spans, footer and comments unchanged

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” 🟢 Empty High/Medium tiers handled via display:none per 12.5/13.5; no other empty ER section
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels and interaction labels match ER bold labels
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢  
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢  
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 ER sections condensed (protocol 11 bullets to 3 cells, interactions trimmed of mechanisms and no-interaction items)

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 duration quoted because value contains a colon
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.10.8 matches QRS.md
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 2026-1011-1201
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢  
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 10/11/2026
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢  
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens with “a natural energy-pathway compound sold as a longevity supplement, draws interest for thinning hair”
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.3 [at_a_glance] is no longer than 70 words 🟢 70 words (wc -w)
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢  
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All five ER ‘Populations who should avoid’ entries present
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 10.3 mg/dL and eGFR below 30 thresholds and calcium-AKG condition preserved
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation in contraindications
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Section populated; ER names populations to avoid
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not empty

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 11 ER interactions included; the two ‘no interaction expected/known’ items omitted
9.3 Individual [caution_items] are formatted as <li></li> 🟢  
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists and calcium-AKG qualifiers preserved; Stemoxydine parenthetical trimmed, not dropped
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation in interactions
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 Section populated
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not empty

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢  
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A ER provides three actionable aspects
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢  
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢  
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three time-to-effect aspects available in ER
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high and benefits_medium set to display: none

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_high and risks_medium set to display: none

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢  
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All four ER table biomarkers listed
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢  

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢  
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five ER qualitative markers listed verbatim

Issues 11/10/2026 12:33

Pass rate 100.00%. No issues found.

Issues 11/10/2026 12:28

  1. 4.2 / 4.3 — Interaction labels not verbatim: The Key Interactions items at QRS lines 555 and 564 insert invented glosses (“hair actives blocking enzymes that AKG fuels:”, “acting on cellular self-recycling:”) into the ER bold labels “Cosmetic prolyl hydroxylase inhibitors (diethyl pyridine-2,4-dicarboxylate, marketed as Stemoxydine)” and “Other autophagy-targeting agents (rapamycin, metformin, spermidine)”.
  2. 9.4 — Mechanistic rationale in item: The Stemoxydine caution item (QRS line 555) carries the mechanistic explanation “blocking enzymes that AKG fuels”, which the item rule excludes.

Fixes 11/10/2026 12:28

  1. 4.2 / 4.3 — Interaction labels restored verbatim: Removed the invented glosses so the items read “Cosmetic prolyl hydroxylase inhibitors (marketed as Stemoxydine)” (trimmed ER parenthetical) and “Other autophagy-targeting agents (rapamycin, metformin, spermidine)” (ER label verbatim).
  2. 9.4 — Mechanistic rationale removed: Dropped “hair actives blocking enzymes that AKG fuels” from the Stemoxydine caution item, leaving only the key fact and the “monitor (theoretical)” rating.

Issues 11/10/2026 12:24

  1. 2.7 — Unexplained specialist jargon remains: “Cosmetic prolyl hydroxylase inhibitors” (line 555), “Other autophagy-targeting agents” (line 564) and “phototrichogram or trichoscopy count” (line 638) are left without plain-language glosses, while other technical terms on the sheet are explained.

Fixes 11/10/2026 12:24

  1. 2.7 — Glossed remaining specialist jargon: Added ER-derived plain-language glosses: “Cosmetic prolyl hydroxylase inhibitors (hair actives blocking enzymes that AKG fuels: Stemoxydine)”, “Other autophagy-targeting agents (acting on cellular self-recycling: …)”, and replaced “phototrichogram or trichoscopy count” with “hairs counted per area on magnified photographs or scalp imaging”.

Issues 11/10/2026 12:22

  1. 2.7 — NSAIDs acronym left unexplained: The Key Interactions item at QRS line 561 reads “Over-the-counter NSAIDs (ibuprofen, naproxen)”, dropping the ER’s expansion “non-steroidal anti-inflammatory drugs” (ER line 286) and leaving the acronym unexplained for lay readers.

Fixes 11/10/2026 12:22

  1. 2.7 — NSAIDs acronym expanded: Changed the Key Interactions item from “Over-the-counter NSAIDs (ibuprofen, naproxen)” to the ER’s label “Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen)”.

Issues 11/10/2026 12:18

  1. 2.7 — Unexplained jargon in interactions: “Thiazide diuretics” (line 557) and “Organic anion transporter 1 substrates” (line 560) drop the plain-language glosses given in the ER (“urine-increasing blood-pressure drugs”; “a kidney protein that clears drugs into urine”), leaving specialist terms unexplained.

Fixes 11/10/2026 12:18

  1. 2.7 — Restored plain-language interaction glosses: Added the ER’s glosses to “Thiazide diuretics (urine-increasing blood-pressure drugs: …)” and “Organic anion transporter 1 (a kidney protein that clears drugs into urine) substrates (…)” in Key Interactions.

Issues 11/10/2026 12:16

  1. 4.5 — Sheet not condensed to A4: The Key Interactions gate (lines 553-565) lists 11 items with full explanatory parentheticals (e.g., “Organic anion transporter 1 (a kidney protein that clears drugs) substrates”, “Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen)”), which together with the rest of the sheet overflows a single A4 page.

Fixes 11/10/2026 12:16

  1. 4.5 — Key Interactions condensed: Trimmed explanatory parentheticals in three Key Interactions items (Stemoxydine “a cosmetic hair active”, organic anion transporter 1 “a kidney protein that clears drugs”, NSAIDs expansion) while keeping all named example drugs, to tighten the sheet toward one A4 page.

Issues 11/10/2026 12:13

  1. 2.7 — Unexplained clinical jargon in gates: Line 546 “Active alopecia areata” gives no plain-language meaning (the Risks card says “autoimmune patchy hair loss”), and line 561 “Over-the-counter NSAIDs” leaves the acronym unexpanded although the ER expands it.

Fixes 11/10/2026 12:13

  1. 2.7 — Unexplained clinical jargon in gates: Changed “Active alopecia areata (theoretical, based on genetic association)” to add “autoimmune patchy hair loss” as a plain-language gloss, and expanded “NSAIDs” to “non-steroidal anti-inflammatory drugs” as in the ER.

Issues 11/10/2026 12:08

  1. 2.2 / 2.13 — Takeaway drops audience framing: The at-a-glance (line 433) ends with “Its hair benefit in people is unknown.”, omitting the ER Conclusion’s framing of AKG as “an early, low-cost experiment” for adults “willing to experiment carefully”, leaving a purely negative takeaway.
  2. 2.7 — Unexplained jargon in interactions: “Cosmetic prolyl hydroxylase inhibitors (Stemoxydine)” (line 555) and “Organic anion transporter 1 substrates” (line 560) appear without the plain-language explanations the ER provides.
  3. 13.4 — Parenthetical kept in risk: risks_low (line 583) retains the parenthetical “(alopecia areata)” in “possible link to autoimmune patchy hair loss (alopecia areata)”.

Fixes 11/10/2026 12:08

  1. 2.2 / 2.13 — Restored experiment framing: Rewrote the closing at-a-glance sentence to the ER Conclusion’s “It remains an early, low-cost experiment; hair benefit in people is unknown.” and tightened earlier wording to stay at 70 words.
  2. 2.7 — Plain-language interaction labels: Added “a cosmetic hair active” to the Stemoxydine item and the ER’s “(a kidney protein that clears drugs)” explanation to the Organic anion transporter 1 item.
  3. 13.4 — Removed risk parenthetical: Changed “possible link to autoimmune patchy hair loss (alopecia areata)” to “possible link to autoimmune patchy hair loss” in risks_low.

Issues 11/10/2026 12:06

  1. 2.7 — Acronyms AKG and eGFR unexpanded: “AKG” is used from action_1_sub (line 450) onward and “eGFR” in the kidney-disease contraindication (line 545) without ever being expanded, although the ER defines both.
  2. 4.2 / 4.3 — Vitamin C label altered: The interaction at line 563 is labelled “Vitamin C, high doses” instead of the ER’s bold label “Vitamin C” verbatim.

Fixes 11/10/2026 12:06

  1. 2.7 — Expanded AKG and eGFR: Added “(alpha-ketoglutarate)” after the first “calcium AKG” in action_1_sub and changed “eGFR below 30” to “eGFR, estimated kidney function, below 30” in the kidney-disease contraindication.
  2. 4.2 / 4.3 — Restored Vitamin C label: Changed the interaction label “Vitamin C, high doses” back to the ER’s verbatim bold label “Vitamin C”.

Issues 11/10/2026 12:04

  1. 2.7 — Specialist jargon in benefits: The Speculative benefits line (QRS line 531) uses “Telogen-to-anagen activation” and “dermal papilla protection” where plain terms (resting follicles entering growth; protection of follicle signaling cells) are available from the ER.

Fixes 11/10/2026 12:04

  1. 2.7 — Plain terms in benefits: Replaced “Telogen-to-anagen activation with topical use” with “Resting follicles entering growth with topical use” and “dermal papilla protection” with “protection of follicle signaling cells” in the Speculative benefits line.